ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis (Fibro-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02969759
Recruitment Status : Not yet recruiting
First Posted : November 21, 2016
Last Update Posted : November 23, 2016
Sponsor:
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:

INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown. The average age of onset of ALS is about 60 years old, and the mean survival of patients is about 2 years. The disease is responsible for a progressive paralysis leading to death from respiratory failure. The only treatment available is the Riluzole, with a very modest efficiency on the progression of the disease. ALS is the third neurodegenerative disease, affecting 6000 persons in France, 150 000 in the world. Among the protagonists involved in the occurrence of the disease, mitochondrial perturbations and protein accumulations seem to be central elements.

OBJECTIVES: To precise the implication of energy and protein metabolism in the sporadic forms of ALS, to identify potential biomarkers of the disease and to test new therapies.

METHODS: The investigators will study cell growth, bioenergetics, mitochondrial dynamics, free-radicals production, presence of cytoplasmic inclusions, cytoskeleton structure and stress response in primary skin fibroblasts obtained from sporadic ALS patients. The study will be conducted over a period of three years in 3 centres specialized respectively in motor neuron diseases, mitochondrial metabolism and neuronal cytoskeleton.

PROSPECTS: If the investigators achieve to identify differences between ALS fibroblasts and controls, the results will be key elements to reinforce the hypothesis of a systemic disease with an important metabolic participation, to better define ALS pathophysiological mechanisms, to find potential biomarkers and to test new therapies.


Condition or disease Intervention/treatment Phase
Sporadic Amyotrophic Lateral Sclerosis Other: Skin Biopsy Early Phase 1

Detailed Description:

The investigators will study fibroblasts derived from sporadic ALS patients.

Clinical parameters will be collected such as sex, age, age of onset, clinical presentation, electrophysiological an respiratory parameters, treatments.

Patients and controls derived fibroblasts will be amplified and cultivated from skin biopsies.

Primary fibroblast cell cultures will be derived from skin biopsies obtained from control subjects and from the patients after obtaining written consent. Amplifications will be performed, from passage 1 to 6, allowing the time for cell cryopreservation of 10 samples per cell line. All experiments will be conducted on cells with similar passage numbers, ranging from 6 to 25, to avoid artefacts due to senescence.

Cell growth of each line will be monitored with the IncuCyte ZOOM® system (Essen Biosciences), a microscope gantry that resides in a cell incubator, and a networked external controller hard drive that gathers and processes image data. Cell growth will be automatically calculated at each time point using the relative cell density (ratio of the occupied area to the total area of the acquired regions).

The respiratory parameters of the fibroblasts will be monitored precisely with an high resolution oxygraph (OROBOROS). Enzymatic activity of each complex of the mitochondrial respiratory chain will be measured by spectrometry, and the mitochondrial membrane potential will be studied with fluorescence microscopy (TMRM probe). The investigators will also study mitochondrial dynamics and the architecture of mitochondrial network with fluorescence microscopy and super-resolution microscopy (SRM, Roper). The production of free radicals will be estimated with probes sensitive to oxidative stress. Finally, a metabolomic study (mass spectrometry QTRAP LC/MS/MS 5500 ABSciex) will be performed to characterise precisely the metabolites in the cells and to assess their metabolic profile.

The investigators will search for protein inclusions (intermediate filaments, TDP43, FUS, ubiquitin) with immuno-fluorescence technics. Western Blots will be performed to study the protein metabolism. The architecture of the cytoskeleton will be analysed in SRM and fluorescence microscopy, and the investigators will try to transfect fibroblasts in order to express Neurofilaments and study the consequences on the cytoskeleton and protein metabolism.

The investigators will study the response of the cells to the stress (hypoxia SCI-tive Dual, starvation), and to senescence (high passage numbers).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Study Start Date : November 2016
Estimated Primary Completion Date : November 2017
Estimated Study Completion Date : November 2019


Arm Intervention/treatment
Patients
ALS defined by El Escorial Criteria.
Other: Skin Biopsy
Controls
Asymptomatic subjects with normal examination.
Other: Skin Biopsy



Primary Outcome Measures :
  1. Kinetics of fibroblast growth [ Time Frame: 24 hours ]
    The growth rates of the fibroblast lines


Secondary Outcome Measures :
  1. Mitochondrial metabolism [ Time Frame: 24 hours ]
    the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases

  2. Protéic metabolism [ Time Frame: 24 hours ]
    The presence of intracytoplasmic inclusion of target protein will be sought.

  3. stress in senescence answer [ Time Frame: 24 hours ]
    the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria :

  • a free signed an written consent
  • aged between 18 and 80 years old
  • ALS defined by El Escorial Criteria
  • normal neurological examination

Exclusion criteria:

  • comorbidity or treatment susceptible to impact on metabolism
  • differential diagnosis suspected, early and late forms (<6 month > 3 years)
  • ALS not defined by El Escorial Criteria
  • withdrawal of consent to participate

Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT02969759     History of Changes
Other Study ID Numbers: 2016/36
First Posted: November 21, 2016    Key Record Dates
Last Update Posted: November 23, 2016
Last Verified: November 2016

Keywords provided by University Hospital, Angers:
Bioenergetics
Protein Metabolism
Sporadic Amyotrophic Lateral Sclerosis

Additional relevant MeSH terms:
Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases